Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Impairment expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Zomedica

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet. It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians. Its TRUFORMA biosensor platform is designed to assist practitioners in the diagnosis of complex conditions. The company was founded by Gerald L. Solensky. on January 7, 2013 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Zomedica reports revenue growth and product advancements amidst profitability challenges

Zomedica's 2022 performance reflects revenue growth and product advancements, though challenges in profitability persist. The company's strategic focus on companion animal healthcare presents growth opportunities through innovation and market stability. Addressing expense management, stock stability, and leveraging market trends will be key for Zomedica's future success.

Zomedica reports robust Q1 earnings, eyes global equine market

Zomedica's Q1 2023 showcased strong revenue growth, particularly driven by TRUFORMA and international sales.
The company's focus on maintaining margins, expanding marketing efforts, and targeting global equine markets positions it for future success.
Challenges include the closure of the cancer assay program and operational hurdles in achieving the 70% gross margin target.
Opportunities lie in the launch of new assays, international expansion, and investor engagement beyond quarterly updates.

Zomedica reports robust Q2 earnings, eyes international expansion and product launches

Zomedica's Q2 performance reflects strong revenue growth and strategic investments for future profitability.
Despite challenges like increased OpEx and lower margins, the company is focused on long-term growth through product launches and market expansion.
Opportunities lie in international market exploration, upcoming product launches, and investor engagement strategies.

Zomedica reports record revenues, eyes global expansion amidst stock challenges

Zomedica's Q3 performance reflects strong revenue growth and strategic acquisitions, despite facing challenges like potential delisting and net losses.
The company's focus on new product launches, international expansion, and partnerships presents opportunities for future growth and market diversification.
Overall, Zomedica aims to drive towards cash flow breakeven by leveraging innovative products and maintaining a strong liquidity position.

Zomedica reports record revenues, eyes profitability through strategic growth

Zomedica's strong financial performance in Q4 2023 and full-year results, coupled with a robust cash position and strategic growth initiatives, position the company for future success.
While facing challenges related to compliance requirements and integration costs, Zomedica's focus on innovation, market expansion, and profitability goals present opportunities for sustained growth.
By balancing operational efficiency, product development, and financial discipline, Zomedica aims to drive revenue growth, enhance market presence, and deliver long-term value to shareholders.

Zomedica reports revenue growth and strong cash position in Q1

Zomedica's Q1 2024 performance showed revenue growth driven by key segments, strong cash position, and focus on operational efficiency. The company faces challenges in managing expenses and achieving aggressive revenue targets. Opportunities lie in expanding product lines, international sales, and maintaining financial strength.

Zomedica reports Q2 revenue growth amidst challenges and opportunities

Zomedica's Q2 performance showed revenue growth but with challenges in sales force and noncash charges.
Strengths include achieving milestones and expanding facilities, while opportunities lie in international expansion.
The company faces the task of managing cash burn and finding a new CFO.
Expectations for the second half of 2024 include revenue growth and operational focus.

Zomedica reports record Q3 revenue, eyes global expansion opportunities

Zomedica's Q3 2024 performance showcased revenue growth, margin strength, and cost reduction efforts, positioning the company for future profitability. Strategic international partnerships and product innovations underscore growth potential.
While challenges in achieving profitability persist, Zomedica's focus on operational efficiency and global expansion presents opportunities for sustained growth. Addressing investor inquiries and executing on strategic initiatives will be key to unlocking future value.
With a solid cash position, ongoing product enhancements, and expansion into new markets, Zomedica is poised for growth. Clear communication on financial targets, operational milestones, and strategic direction will be crucial for investor confidence and market success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Asensus Surgical

Iterum Therapeutics Plc

Onconova Therapeutics

Biotech penny stocks continue to see momentum; should you add these 3 to your watchlist? The post Top Biotech Penny Stocks to Buy?

Top Biotech Penny Stocks to Buy? 4 Biotech Stocks to Watch Before May 2021

Zomedica (ZOM) stock is taking off on Thursday despite a lack of news concerning the maker of medical devices for veterinarians. The post ZOM Stock: What Zomedica Investors Are Saying as the Pet Pharma Play Rallies appeared first on InvestorPlace.

ZOM Stock: What Zomedica Investors Are Saying as the Pet Pharma Play Rallies

HUMBL

Ideanomics Inc

With tech penny stocks in focus, which companies should you watch? The post Tech Penny Stocks to Buy in 2021?

Tech Penny Stocks to Buy in 2021? Check These 3 Out

Despite releasing Truforma ahead of schedule, Zomedica still has to overcome tough challenges facing the product. Investors should not buy ZOM stock yet.

Despite Recent Progress, Zomedica Has to Prove Its Value

These ultra-popular Reddit stocks are fooling unsuspecting investors with their low share prices.

If You Think AMC, Sundial, and Zomedica Are Cheap, I Have Bad News

Initial sales of a key product may be lower than investors were hoping for.

Why Zomedica Stock Plunged Today

The stock price of Zomedica Corp (NYSEAMERICAN: ZOM) fell by over 10% during intraday trading. This is why it happened.

ZOM Stock: Over 10% Decrease Intraday Explanation

After falling back to $1 per share, expect headline-making "meme stock" ZOM stock to give up even more of its recent gains. The post The Party's Over for Zomedica Stock, So Stay Away appeared first on InvestorPlace.

The Party's Over for Zomedica Stock, So Stay Away

For those who have been waiting for a big discount in ZOM stock, it has arrived. Still, you may want to rethink this before committing.

Zomedica's Price Has Changed but So Has the Narrative

ANN ARBOR, Mich., April 15, 2021 (GLOBE NEWSWIRE) -- Zomedica Corp. (NYSE American: ZOM) (“Zomedica” or the “Company”), a veterinary health company creating point-of-care diagnostics products for dogs and cats, announced that it intends to expand its direct sales organization while phasing out its distributor-based sales efforts.

Zomedica to Build Direct Sales Force for TRUFORMA® Platform

The stock has been falling sharply in the past month.

Should You Buy Zomedica in April?

The shares of Zomedica Corp (NYSEAMERICAN: ZOM) fell by 10.71% today. This is why it happened.

ZOM Stock: 10.71% Decrease Explanation

Zomedica Could Be A Buy As They Look To Disrupt The Veterinary Diagnostics Field

Castor Maritime Inc

Genius Brands

Hall of Fame Resort & Entertainment

Cenntro Electric Group

Ocugen, Inc.

SNDL Inc.

Once flying high on their status as Reddit stocks, these nine penny stocks are falling back towards prior price levels. The post 9 Reddit Penny Stocks That Are Running Out of Gas appeared first on InvestorPlace.

9 Reddit Penny Stocks That Are Running Out of Gas

The past year has been great for pet-related stocks, and ZOM stock is as much a perfect example as it is a cautionary tale. The post Zomedica Really Only Has Its Penny Status Keeping It Interesting appeared first on InvestorPlace.

Zomedica Really Only Has Its Penny Status Keeping It Interesting

Has ZOM stock bottomed or does it have further to fall? Investors who are interested in buying stock of animal health company Zomedica may want to pull the trigger with the share price down 47% since March 15.

Zomedica Stock Pullback Opens Door for Investors To Take a Small Position

GameStop

Marathon Digital Holdings

Riot Blockchain

With gains of 1,259% to 2,801%, these billion-dollar stocks have been unstoppable since early October.

5 Stocks That Made People Millionaires in 6 Months

The retirement of preferred stock seems like a clear win for Zomedica and ZOM stock. But the deal raises a key question as well.

You Don't Want to Be the Last to Know What Zomedica Stock Is Realy Worth

The early launch of Zomedica's Truforma does not guarantee commercial success. Before you bet on ZOM stock, the company needs to prove itself.

Do Not Bet on Zomedica… At Least Not Yet

BlackBerry

Churchill Capital Corp IV

Koss

Meme stocks have exhausted investors this year, and we're only through the first quarter. Retail investors have taken to social media sites such as WallStreetBets on Reddit to work themselves and others into an irrational frenzy over stocks that they then pump up to unreasonable and unsustainable levels.

4 Popular Meme Stocks That Aren't Worth the Hype

American Airlines

AMC Entertainment

Cassava Sciences Inc

These high-flying stocks may soon reverse course.

5 Ultra-Popular Stocks to Avoid Like the Plague in April

ZOM stock is climbing higher today, reversing recent gains. However, a new Bloomberg report says it could be yesterday's news.

ZOM Stock: Is Zomedica Out of Favor With Meme Stocks Investors?

ZOM stock fell sharply after the March 16 launch of its veterinary platform. It needs solid sales before they will rise substantially again.

ZOM Stock Will Keep Losing Steam Until Fundamentals Show Strength

The interest in ZOM stock is purely speculative. There is absolutely zero reason to chase it stemming from the current fundamentals.

Zomedica Stock Is Not for the Casual Investor

These brand-name and under-the-radar stocks delivered game-changing returns to start the year.

News for Zomedica Stock (ZOM)